Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:90:101104.
doi: 10.1016/j.mam.2022.101104. Epub 2022 Jul 11.

Siglecs in allergy and asthma

Bruce S Bochner  1 , Jeremy A O'Sullivan  2 , Alan T Chang  3 , Bradford A Youngblood  3
Affiliations
Review

Siglecs in allergy and asthma

Bruce S Bochner et al. Mol Aspects Med. 2023 Apr.

Abstract

The term "allergic diseases" encompasses several common, IgE-mediated conditions that range from being annoying to those that are life-threatening. Available treatments include active avoidance of the instigating allergen and the use of a variety of oral, inhaled, intranasal, intraocular and injected agents. While most individuals with allergies do well with existing therapies, there are still unmet therapeutic needs. Siglecs (sialic acid-binding, immunoglobulin-like lectins) are a family of single-pass transmembrane I-type lectins found on various subsets of cells, especially those of the immune system. All Siglecs have extracellular domains recognizing sialoside ligands, and most contain cytoplasmic domains with inhibitory signaling activity. This review focuses on Siglecs that likely play a role in regulating allergic and asthmatic responses, and how specific Siglecs, expressed on cells such as eosinophils and mast cells, are being targeted for therapeutic benefit.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest B.S.B. receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He receives publication-related royalty payments from Elsevier and UpToDate. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. B.S.B. is also a co-founder of Allakos, Inc. which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. J.A.O. has nothing to disclose. A.T.C and B.A.Y. are current employees of and/or own stock and/or stock options from Allakos, Inc.

Figures

Figure 1.
Figure 1.
Sequential events resulting in the development of allergic reactivity.
Figure 2.
Figure 2.
Type 2 cytokines, their predominant sources, and examples of important functions in humans.
Figure 3.
Figure 3.
Mouse and human Siglecs, with a focus on those expressed on cells involved in allergy and asthma.
See this image and copyright information in PMC

References

    1. Akula S, Paivandy A, Fu Z, Thorpe M, Pejler G, Hellman L, 2020. Quantitative in-depth analysis of the mouse mast cell transcriptome reveals organ-specific mast cell heterogeneity. Cells 9 (1), 211. doi: 10.3390/cells9010211. - DOI - PMC - PubMed
    1. Altrichter S, Staubach P, Pasha M, Singh B, Chang AT, Bernstein JA, Rasmussen HS, Siebenhaar F, Maurer M, 2021. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2021.12.772. Online ahead of print. - DOI - PubMed
    1. Anesi SD, Tauber J, Nguyen QD, Chang P, Berdy GJ, Lin CC, Chu DS, Levine HT, Fernandez AD, Roy N, Asbell PA, Kantor AM, Chang AT, Singh B, Youngblood BA, Jeng BH, Jhanji V, Rasmussen HS, Foster CS, 2022. Lirentelimab for severe and chronic forms of allergic conjunctivitis. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2022.03.021. Online ahead of print. - DOI - PubMed
    1. Angata T, Margulies EH, Green ED, Varki A, 2004. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc. Natl. Acad. Sci. USA 101 (36), 13251–13256. - PMC - PubMed
    1. Angata T, Nycholat CM, Macauley MS, 2015. Therapeutic targeting of siglecs using antibody- and glycan-based approaches. Trends Pharmacol. Sci. 36 (10), 645–660. - PMC - PubMed

Substances